Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins... Show more
The Aroon Indicator for GIKLY entered a downward trend on November 12, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In of the 232 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on November 10, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GIKLY as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for GIKLY turned negative on November 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (9.612). P/E Ratio (19.476) is within average values for comparable stocks, (23.835). Projected Growth (PEG Ratio) (0.236) is also within normal values, averaging (2.037). Dividend Yield (0.014) settles around the average of (0.028) among similar stocks. P/S Ratio (0.962) is also within normal values, averaging (3.560).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GIKLY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GIKLY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
Industry PharmaceuticalsMajor
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HFXI | 32.74 | 0.21 | +0.63% |
| NYLI FTSE International Eq Ccy Netrl ETF | |||
| BNY | 10.22 | 0.04 | +0.39% |
| BlackRock New York Municipal Income Trust | |||
| BKSE | 111.09 | 0.36 | +0.33% |
| BNY Mellon US Small Cap Core Equity ETF | |||
| JMID | 29.67 | 0.02 | +0.08% |
| Janus Henderson Mid Cap Growth Alpha ETF | |||
| BCOR | 29.97 | -0.35 | -1.16% |
| Grayscale Bitcoin Adopters ETF | |||
A.I.dvisor indicates that over the last year, GIKLY has been closely correlated with GRFS. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GIKLY jumps, then GRFS could also see price increases.
| Ticker / NAME | Correlation To GIKLY | 1D Price Change % | ||
|---|---|---|---|---|
| GIKLY | 100% | +2.38% | ||
| GRFS - GIKLY | 68% Closely correlated | -0.46% | ||
| GIFOF - GIKLY | 27% Poorly correlated | N/A | ||
| GIFLF - GIKLY | 25% Poorly correlated | N/A | ||
| ORINY - GIKLY | 9% Poorly correlated | N/A | ||
| OPHLY - GIKLY | 8% Poorly correlated | +1.37% | ||
More | ||||